1031602-63-7
1031602-63-7 結(jié)構(gòu)式
基本信息
5-(環(huán)己烷甲酰胺基)-2-(苯基氨基)噻唑-4-甲酰胺
5-[(Cyclohexylcarbonyl)amino]-2-(phenylamino)-thiazolecarboxamide
2-anilino-5-(cyclohexanecarbonylamino)-1,3-thiazole-4-carboxamide
4-Thiazolecarboxamide, 5-[(cyclohexylcarbonyl)amino]-2-(phenylamino)-
物理化學性質(zhì)
DMF:30.0(Max Conc. mg/mL);87.1(Max Conc. mM)
Ethanol:0.2(Max Conc. mg/mL);0.58(Max Conc. mM)
常見問題列表
IC50: ~41 nM (Phosphatidylinositol 4-phosphate 5 kinase type 1C (PIP5K1C))
Membrane PIP2 levels are significantly reduced by ~45% in dorsal root ganglia (DRG) neurons treated with 100 nM UNC3230 (~2-fold above the IC50) relative to vehicle controls. UNC3230 significantly reduces lysophosphatidic acid (LPA)-evoked calcium signaling in cultured DRG neurons relative to vehicle.
UNC3230 (2 nmol) significantly increases noxious heat-evoked paw withdrawal latency for two hours after intrathecal injection in wild-type mice, indicating an antinociceptive effect.
UNC3230 (2 nmol; intrathecal injection) is administered then one hour later co-injected 1 nmol LPA with UNC3230 (2 nmol, intrathecal injection). UNC3230 significantly blunts thermal hyperalgesia and mechanical allodynia compared to vehicle.
UNC3230 (2 nmol; intrathecal injection) significantly blunts thermal hyperalgesia and mechanical allodynia in the complete Freund’s adjuvant (CFA)-inflamed hindpaw (relative to vehicle control) but does not affect thermal or mechanical sensitivity in the control (non-inflamed) hindpaw over a multiday time course.